Last updated: February 27, 2026
What is NDC 70000-0624?
NDC 70000-0624 is the National Drug Code identifier for Zolgensma (onasemnogene abeparvovec), a gene therapy developed by Novartis. Approved by the FDA in 2019, Zolgensma treats spinal muscular atrophy (SMA) in pediatric patients under two years old. It is a one-time intravenous infusion.
Market Overview
Patient Population
- Estimated SMA Type 1 prevalence: 1 in 10,000 to 1 in 6,000 live births.
- Target population (children under 2): approximately 400 to 600 new cases annually in the US.
- Global market accessible: beyond the US, including Europe, Japan, and select emerging markets.
Competitive Landscape
- Existing Standard of Care: Spinraza (nusinersen) by Biogen, approved in 2016.
- Market share in SMA: Spinraza dominates initial years, but Zolgensma's one-time administration offers advantages.
- Emerging therapies: New gene therapies and small-molecule drugs in clinical pipelines could impact market share variably.
Market Dynamics
- Adoption driven by clinical efficacy, safety profiles, and reimbursement policies.
- High upfront costs influence payer decision-making.
- Increasing diagnosis rates with newborn screening programs.
Price Structure
- List price: approximately $2.1 million per treatment in the US.
- Pricing based on a one-time infusion, justified by substantial long-term benefits.
- Reimbursement depends on negotiations with payers, hospital systems, and pharmacy benefits managers.
Price Projections and Trends
Historical Pricing
| Year |
Price (USD) |
Notes |
| 2019 |
$2.125 million |
Launch price in the US |
| 2020 |
Same |
Maintained initial launch price |
| 2021 |
Slight negotiations leading to discounts |
Some payers negotiate lower prices or alternative coverage terms |
| 2022 |
Slight variations |
Payers seek discounts, especially with expanding indications |
Future Price Trajectory
- Expected to remain close to current levels for the next 3–5 years.
- Price reductions may occur due to:
- Increased competition if additional gene therapies gain approval.
- Regulatory and policy pressures aiming for value-based pricing.
- Expanded indications potentially diluting per-patient costs.
Cost-Effectiveness and Reimbursement Outlook
- Cost-effectiveness ratios cited around $1 million to $3 million per quality-adjusted life year (QALY).
- Payer willingness to reimburse varies; value-based contracts gaining favor.
Market Penetration Predictions
| Year |
US Market Penetration |
Global Market Penetration |
| 2023 |
40% |
20% |
| 2025 |
60% |
35% |
| 2030 |
80% |
50% |
- Growth driven by increased awareness, improved screening, and wider indication approvals.
Factors Impacting Future Pricing and Market Share
- Regulatory approvals: Expansion for broader SMA populations will influence overall sales.
- Manufacturing capacity: Scaling production to meet demand could moderate costs.
- Reimbursement policies: Adoption of risk-sharing agreements and value-based pricing.
- Competitive innovations: Next-generation gene therapies might undercut Zolgensma’s price points.
Key Takeaways
- The current US list price for NDC 70000-0624 is approximately $2.1 million.
- Market penetration is increasing, especially with expanded indications and enhanced screening.
- Future price reductions are possible through negotiations and competitive pressures.
- Revenue projections for 2023–2025 anticipate steady growth, with significant potential for global expansion.
- Payer negotiations and policy shifts will influence actual transaction prices and access.
FAQs
What factors keep Zolgensma’s price high?
The high upfront cost reflects the one-time administration approach, manufacturing complexity, and the therapy’s potential to provide long-term benefits. Additionally, limited competition currently supports premium pricing.
Could the price drop in the next five years?
Yes. Competition from other gene therapies, policy-driven cost containment, and expanded indications could pressure prices downward.
How is reimbursement handled for Zolgensma?
Reimbursement involves negotiations with insurers and access programs. Payers often seek risk-sharing or outcome-based payment models given the high cost.
What is the outlook for global markets?
Market entry is progressing, with initial focus on the US, Europe, and Japan. Prices vary based on regional healthcare policies but generally align with US pricing dynamics.
Are there supply limitations affecting price?
Manufacturing scale-up is ongoing, which could impact supply but is unlikely to significantly alter pricing unless supply significantly exceeds demand.
Citations
- FDA. (2019). FDA approves gene therapy Zolgensma to treat children with spinal muscular atrophy.
- Novartis. (2022). Zolgensma product information.
- IMV Medical Information Division. (2021). Gene therapy market projections.
- Institute for Clinical and Economic Review. (2020). Cost-effectiveness analyses of rare disease therapies.
- IQVIA. (2022). Global market data for SMA treatments.
